PortalPublikationenRegulation of IL-22BP in psoriasis

Regulation of IL-22BP in psoriasis

Standard

Regulation of IL-22BP in psoriasis. / Voglis, Stefanos; Moos, Sonja; Kloos, Luise; Wanke, Florian; Zayoud, Morad; Pelczar, Penelope; Giannou, Anastasios D; Pezer, Silvia; Albers, Michael; Luessi, Felix; Huber, Samuel; Schäkel, Knut; Kurschus, Florian C.

in: SCI REP-UK, Jahrgang 8, 23.03.2018, S. 5085.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Voglis, S, Moos, S, Kloos, L, Wanke, F, Zayoud, M, Pelczar, P, Giannou, AD, Pezer, S, Albers, M, Luessi, F, Huber, S, Schäkel, K & Kurschus, FC 2018, 'Regulation of IL-22BP in psoriasis', SCI REP-UK, Jg. 8, S. 5085. https://doi.org/10.1038/s41598-018-23510-3

APA

Voglis, S., Moos, S., Kloos, L., Wanke, F., Zayoud, M., Pelczar, P., Giannou, A. D., Pezer, S., Albers, M., Luessi, F., Huber, S., Schäkel, K., & Kurschus, F. C. (2018). Regulation of IL-22BP in psoriasis. SCI REP-UK, 8, 5085. https://doi.org/10.1038/s41598-018-23510-3

Vancouver

Voglis S, Moos S, Kloos L, Wanke F, Zayoud M, Pelczar P et al. Regulation of IL-22BP in psoriasis. SCI REP-UK. 2018 Mär 23;8:5085. https://doi.org/10.1038/s41598-018-23510-3

Bibtex

@article{f5941348d3d9450ab4555aa74ab1f704,
title = "Regulation of IL-22BP in psoriasis",
abstract = "IL-22 is a potent pro-inflammatory cytokine upregulated in psoriasis and in other inflammatory diseases. The function of IL-22 is regulated by the soluble scavenging receptor, IL-22 binding protein (IL-22BP or IL-22RA2). However, the role and regulation of IL-22BP itself in the pathogenesis of inflammatory disease remain unclear. We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ. We also analysed psoriatic skin of patients and compared this to skin of healthy donors. Interestingly, IL-22BP expression was similarly downregulated in skin biopsies of psoriasis patients compared to the skin of healthy donors. Since IL-22BP is expressed foremost in dendritic cells, we characterized its expression in monocyte-derived dendritic cells (MoDC) during maturation. In this way, we found Prostaglandin E2 (PGE2) to be a potent suppressor of IL-22BP expression in vitro. We conclude that regulation of IL-22BP by inflammatory mediators is an important step for the progression of inflammation in the skin and possibly also in other autoimmune diseases.",
keywords = "Journal Article",
author = "Stefanos Voglis and Sonja Moos and Luise Kloos and Florian Wanke and Morad Zayoud and Penelope Pelczar and Giannou, {Anastasios D} and Silvia Pezer and Michael Albers and Felix Luessi and Samuel Huber and Knut Sch{\"a}kel and Kurschus, {Florian C}",
year = "2018",
month = mar,
day = "23",
doi = "10.1038/s41598-018-23510-3",
language = "English",
volume = "8",
pages = "5085",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",

}

RIS

TY - JOUR

T1 - Regulation of IL-22BP in psoriasis

AU - Voglis, Stefanos

AU - Moos, Sonja

AU - Kloos, Luise

AU - Wanke, Florian

AU - Zayoud, Morad

AU - Pelczar, Penelope

AU - Giannou, Anastasios D

AU - Pezer, Silvia

AU - Albers, Michael

AU - Luessi, Felix

AU - Huber, Samuel

AU - Schäkel, Knut

AU - Kurschus, Florian C

PY - 2018/3/23

Y1 - 2018/3/23

N2 - IL-22 is a potent pro-inflammatory cytokine upregulated in psoriasis and in other inflammatory diseases. The function of IL-22 is regulated by the soluble scavenging receptor, IL-22 binding protein (IL-22BP or IL-22RA2). However, the role and regulation of IL-22BP itself in the pathogenesis of inflammatory disease remain unclear. We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ. We also analysed psoriatic skin of patients and compared this to skin of healthy donors. Interestingly, IL-22BP expression was similarly downregulated in skin biopsies of psoriasis patients compared to the skin of healthy donors. Since IL-22BP is expressed foremost in dendritic cells, we characterized its expression in monocyte-derived dendritic cells (MoDC) during maturation. In this way, we found Prostaglandin E2 (PGE2) to be a potent suppressor of IL-22BP expression in vitro. We conclude that regulation of IL-22BP by inflammatory mediators is an important step for the progression of inflammation in the skin and possibly also in other autoimmune diseases.

AB - IL-22 is a potent pro-inflammatory cytokine upregulated in psoriasis and in other inflammatory diseases. The function of IL-22 is regulated by the soluble scavenging receptor, IL-22 binding protein (IL-22BP or IL-22RA2). However, the role and regulation of IL-22BP itself in the pathogenesis of inflammatory disease remain unclear. We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ. We also analysed psoriatic skin of patients and compared this to skin of healthy donors. Interestingly, IL-22BP expression was similarly downregulated in skin biopsies of psoriasis patients compared to the skin of healthy donors. Since IL-22BP is expressed foremost in dendritic cells, we characterized its expression in monocyte-derived dendritic cells (MoDC) during maturation. In this way, we found Prostaglandin E2 (PGE2) to be a potent suppressor of IL-22BP expression in vitro. We conclude that regulation of IL-22BP by inflammatory mediators is an important step for the progression of inflammation in the skin and possibly also in other autoimmune diseases.

KW - Journal Article

U2 - 10.1038/s41598-018-23510-3

DO - 10.1038/s41598-018-23510-3

M3 - SCORING: Journal article

C2 - 29572462

VL - 8

SP - 5085

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

ER -